Australia - engelsk - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - formoterol fumarate dihydrate, quantity: 6 microgram; beclometasone dipropionate, quantity: 200 microgram; glycopyrronium bromide, quantity: 12.5 microgram (equivalent: glycopyrronium, qty microgram) - inhalation, pressurised - excipient ingredients: ethanol absolute; norflurane; dilute hydrochloric acid - asthma trimbow 200/6/10 maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - budesonide and formoterol fumarate dihydrate inhalation aerosol is indicated for the treatment of asthma in patients 6 years of age and older. budesonide and formoterol fumarate dihydrate inhalation aerosol should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2-adrenergic agonist (laba). important limitations of use: budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is also indicated to reduce exacerbations of copd. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is the only strength indicated for the treatment of copd. important limitat

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - budesonide (unii: q3oks62q6x) (budesonide - unii:q3oks62q6x), formoterol fumarate (unii: w34shf8j2k) (formoterol - unii:5zz84gcw8b) - budesonide and formoterol fumarate dihydrate inhalation aerosol is indicated for the treatment of asthma in patients 6 years of age and older. budesonide and formoterol fumarate dihydrate inhalation aerosol should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ics) or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long-acting beta2-adrenergic agonist (laba). important limitations of use: budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is also indicated to reduce exacerbations of copd. budesonide and formoterol fumarate dihydrate inhalation aerosol 160/4.5 is the only strength indicated for the treatment of copd. important limitat

Kenya - engelsk - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki vihar road, andheri (east) - - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Kenya - engelsk - Pharmacy and Poisons Board

bliss gvs pharma limited 102, hyde park, saki-vihar road, andheri (east), - formoterol fumarate dihydrate bp and budesonide bp - pressurised inhalation - formoterol fumarate dihydrate bp equivalent to… - formoterol and budesonide

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - 44098 - information system software, application program, cardiology - this device is a cardiology information system whichis intended to store, access and manage cardiovascular information on adult and pediatric patients. the information consists of measurements, text, and digitized waveforms. this cardiology information system is intended to provide the ability to review and edit electrocardiographic procedures on screen, through the use of reviewing, measuring, and editing tools including ecg serial comparison and interpretive 12-lead analysis. this device is intended to be used under the direct supervision of a licensed healthcare practitioner, by trained operators in a hospital or facility providing patient care. this cardiology information system is not intended for real-time patient monitoring or for pediatric serial comparison.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

aro systems pty ltd - 44105 - information system software, application program, physician practice management - radiology information system for optimising the radiology workflow. to administer patient data, document patient visits and performed studies, the related findings, documents, diagnoses, as well as the liquidation of the rendered services. it is further possible to create and print automatically generated reports in word processing programs.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - formoterol fumarate 12ug - powder filled inhalation capsule - 12 mcg - active: formoterol fumarate 12ug excipient: gelatin ink lactose monohydrate - foradil is indicated for the treatment of bronchoconstriction in adults and children six years of age and over with asthma as an add-on to inhaled corticosteroid (ics) treatment. in the management of asthma, foradil should be used only as an adjunct to corticosteroids. foradil should not be used in the treatment of acute asthmatic symptoms, or in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists.

Den europeiske union - engelsk - EMA (European Medicines Agency)

astrazeneca ab - glycopyrronium, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive - formoterol and glycopyrronium bromide - bevespi aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Israel - engelsk - Ministry of Health

kamada ltd, israel - beclometasone dipropionate; formoterol fumarate dihydrate; glycopyrronium as bromide - pressurised solution - glycopyrronium as bromide 9 mcg/delivered dose; formoterol fumarate dihydrate 5.2 mcg/delivered dose; beclometasone dipropionate 87.4 mcg/delivered dose - formoterol, glycopyrronium bromide and beclometasone - copd maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist. asthma maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.…